Pharmacokinetic and pharmacodynamic parameters of antimicrobials: Potential for providing dosing regimens that are less vulnerable to resistance

Clinical Pharmacokinetics

Volumn 48, Issue 8, 2009, Pages 517-528

  Adembri, Chiara ^a   Novelli, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DRUG DOSE REGIMEN; ERADICATION THERAPY; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 69249124938     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/10895960-000000000-00000     Document Type: Review

References (83)

1. Fish DN, Ohlinger MJ. Antimicrobial resistance: factors and outcomes. Crit Care Clin 2006; 22 (2): 291-311
2. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999; 20 (2): 303-16
3. Singh N, Yu VL. Rational empiric antibiotic prescription in the ICU. Chest 2000; 117 (5): .1496-9
4. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003. Am. J Infect Control 2003; 31 (8): 481-98
5. Huskins WC. Interventions to prevent transmission of antimicrobial- resistant bacteria in the intensive care unit. Curr Opin Crit Care 2007; 13 (5): 572-7
6. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued. October 2004. Am. J Infect Control. 2004; 32 (8): 470-85
7. Klevens RM, Edwards JR, Tenover FC, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin infect Dis 2006; 42 (3): 389-91
8. European Antimicrobial Resistance Surveillance System [EARSS]. EARSS annual report 2006 Bilthoven; EARSS, 2007 Oct. [online]. Available from URL: http://www.rivm.nl/earss/Images/EARSS%202006%20Def-tcm6144176.pdf [Accessed 2008 Aug 1]
9. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokineticpharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006; 42(12): 1764-71
10. Pangault C, Le Tulzo Y, Tattevin P, et al. Down-modulation, of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock. Crit Care Med 2006; 34 (4): 1193-201
11. Tarn VH, Louie A, Fritsche TR, et al. Impact of drug-exposure intensity and duration, of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 2007; 195 (12): 1818-27
12. Drusano GL, Louie A, Deziel M, et al. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis 2006; 42 (4): 525-32
13. DeRyke CA, Lee SY, Kuti JL, et al. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66 (1): 1-14
14. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Infect Control 2006; 34 (5 Suppl. 1): S38-45
15. Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin. Infect Dis 2007; 45 Suppl, 2: S129-36
16. Eagle H, Fleischmann R, Musselman AD. Effect, of schedule of administration on the therapeutic efficacy of penicillin: importance of the aggregate time penicillin remains at effectively bactericidal levels. Am J Med 1950; 9 (3): 280-99
17. Ambrose PG, Bhavnani. SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44 (1): 79-86
18. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007; 45 Suppl. 1: S89-95
19. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004; 30 (12): 2145-56
20. Garraffo R. Optimal adaptive control of pharmacodynamic effects with aminoglycoside antibiotics: a required approach for the future. Int J Biomed Comput 1994; 36 (1.-2): 43-57
21. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26 (1): 1-10
22. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20 (3): 391-408
23. Moise-Broder PA, Forrest A. Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43 (13): 925-42
24. Bakker-Woudenberg IA, ten Kate MT, Goessens WH, et al. Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection. Antimicrob Agents Chemother 2006; 50 (9): 2919-25
25. Negri MC, Morosini MI, Loza E, et al. In vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant Streptococcus pneumoniae populations. Antimicrob Agents Chemother 1994; 38 (1): 122-5
26. Negri MC, Lipsitch M, Blazquez J, et al. Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. Antimicrob Agents Chemother 2000; 44 (9): 2485-91
27. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007; 44 (5): 681-8
28. Lodise Jr TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44 (3): 357-63
29. LaPlante KL, Rybak MJ, Tsuji B, et al. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 2007; 51 (4): 1315-20
30. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; .112 (2): 275-85
31. Zinner SH, Lubenko IY, Gilbert D, et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial, killing. J Antimicrob Chemother 2003; 52 (4): 616-22
32. Tam VH, Schilling AN, Neshat S, et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49 (12): 4920-7
33. Alou L, Gimenez MJ, Sevillano D, et al. A pharmacodynamic approach, to antimicrobial activity in serum and epithelial, lining fluid against in vivoselected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. J Antimicrob Chemother 2006; 58 (2): 349-58
34. Rose WE, Rybak MJ, Tsuji BT, et al. Correlation, of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (AGR) polymorphism and function. J Antimicrob Chemother 2007; 59 (6): 1190-3
35. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillinclavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42 (9): 2375-9
36. Fitoussi F, Doit C, Sandin A, et al. Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile. Antimicrob Agents Chemother 1995; 39 (11): 2560-3
37. Odenholt I, Gustafsson I, Lowdin E, et al. Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob Agents Chemother 2003; 47 (2): 518-23
38. Knudsen JD, Odenholt I. Erlendsdottir H, et al. Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob Agents Chemother 2003; 47 (8): 2499-506
39. Goessens WH, Mouton JW, ten Kate MT, et al. Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection. J Antimicrob Chemother 2007; 59 (3): 507-16
40. Firsov AA, Vostrov SN, Lubenko IY, et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47 (5): 1604-13
41. Olofsson SK, Geli P, Andersson DI, et al. Pharmacodynamic model, to describe the concentration-dependent selection, of cefotaxime-resistant Escherichia coll. Antimicrob Agents Chemother 2005; 49 (12): 5081-91
42. Mattie H. Antibiotic efficacy in vivo predicted by in vitro activity. Int J Antimicrob Agents 2000; .14 (2): 91-8
43. Bent LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol. Ther 2002; 71 (3): 115-21
44. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37 (5): 1073-81
45. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42 (3): 521-7
46. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279 (2): 125-9
47. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189 (9): 1.590-7
48. Ambrose PO, Grasela DM, Grasela TH, et al, Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45 (10): 2793-7
49. Weinstein MP, Stratton CW, Hawley HB, et al. Multicenter collaborative evaluation, of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987; 83 (2): 218-22
50. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27(l): 10-22
51. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15 (3): 255-9
52. Sadaba B, Azanza JR, Campanero MA, et al. Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome. Clin Microbiol Infect 2004; 10 (11): 990-8
53. Guillemot D, Carbon. C, Balkan B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998; 279 (5): 365-70
54. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001; 286(1): 49-56
55. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31 (4): 345-51
56. Roos JF, Bulitta J, Lipman J, et al. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006; 58 (5): 987-93
57. Lodise TP, Preston S, Bhargava V, et al, Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn Microbiol Infect Dis 2005; 52 (1): 45-52
58. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused, by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43 (3): 623-9
59. Zelenitsky SA, Harding GK, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003; 52 (4): 668-74
60. Burkhardt O, Lehmann C, Madabushi R, et al. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than, thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 2006; 58 (4): 822-9
61. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290 (19): 2588-98
62. Novelli A, Adembri C, Livi P, et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44 (5): 539-49
63. Tarn VH, Gamez EA, Weston JS, et al, Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008; 46 (6): 862-7
64. Lee SY, Fan HW, Sutherland C, et al. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus. Drugs R D 2007; 8 (2): 69-77
65. Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007; 59 (2): 277-84
66. US National Committee for Clinical Laboratory Standards [NCCLS], Clinical Laboratory Standards Institute [CLSI]. Performance standards for antimicrobial susceptibility testing: fourteenth international supplement M100S14, Wayne (PA): CLSI, 2004 Jan
67. European. Committee on Antimicrobial Susceptibility Testing, European Society of Clinical Microbiology and Infectious Diseases. Clinical breakpoints [online]. Available from http://www.srga.org/eucastwt/MICTAB/index. html [Accessed 2009 Jul 14]
68. Drusano GL, Ambrose PG, Bhavnani SM, et al, Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45 (6): 753-60
69. Novelli A, Mazzei T, Fallani S, et al. Clinical pharmacokinetics and tissue penetration of netilmicin given once versus twice daily. J Chemother 1991; 3 Suppl. 4: 229-32
70. Blaser J, Simmen HP, Thurnheer U, et al. Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections. J Antimicrob Chemother 1995; 36 (5): 803-14
71. Chambers HF. Aminoglycosides. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's: the pharmacological basis of therapeutics. 11 th ed. New York: McGraw-Hill, 2006
72. Zaske DE, Cipolle RJ, Rotschafer JC, et al. Gentamicin pharmacokinetics in 1640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982; 21 (3): 407-11
73. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28 (2): 143-60
74. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13 (5): 598-606
75. Mouton JW, Punt N, Vinks AA. Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. Antimicrob Agents Chemother 2007; 51 (9): 3449-51
76. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, et al, Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and Ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989; 8 (10): 878-87
77. Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22 (4): 471-83
78. Buerger C, Plock N, Dehghanyar P, et al. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006; 50 (7): 2455-63
79. MacGowan AP. .Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl. 2:ii17-25
80. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008; 31 (2): 122-9
81. Boak LM, Li J, Rayner CR, et al, Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother 2007; 51 (4): 1287-92
82. Louie A, Heine HS, Kim K, et al. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus antkracis. Antimicrob Agents Chemother 2008; 52 (7): 2486-96
83. MacKenzie FM, Struelens MJ, Towner KJ, et al. Report of the Consensus Conference on Antibiotic Resistance; Prevention and Control (ARPAC). Clin Microbiol Infect 2005; 11 (11): 938-54